Disc Medicine Announces Multiple Presentations Across Portfolio At The 65th American Society Of Hematology Annual Meeting And Key Program Updates
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine, Inc. (NASDAQ:IRON) has announced the completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP). The company will present preliminary data from these studies and from phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia at the 65th American Society of Hematology (ASH) Annual Meeting. The company will also host a conference call on December 11th to discuss these updates.
November 02, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine's completion of enrollment for phase 2 studies and upcoming presentations at the ASH meeting could potentially boost investor confidence.
The completion of enrollment for phase 2 studies indicates progress in Disc Medicine's drug development pipeline, which could positively impact the company's stock. The upcoming presentations at the ASH meeting could potentially boost investor confidence if the preliminary data shows promising results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100